CervoMed (CRVO) vs. Its Rivals Head to Head Analysis

CervoMed (NASDAQ:CRVO) is one of 1,078 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare CervoMed to related companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, earnings and dividends.

Risk and Volatility

CervoMed has a beta of -0.73, suggesting that its stock price is 173% less volatile than the S&P 500. Comparatively, CervoMed’s peers have a beta of 4.18, suggesting that their average stock price is 318% more volatile than the S&P 500.

Earnings and Valuation

This table compares CervoMed and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CervoMed	$7.14 million	-$2.17 million	-3.43
CervoMed Competitors	$9.91 billion	$136.15 million	-5.39

CervoMed’s peers have higher revenue and earnings than CervoMed. CervoMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations for CervoMed and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1	1	5	2	2.89
CervoMed Competitors	8824	22869	51334	1438	2.54

CervoMed presently has a consensus target price of $27.63, indicating a potential upside of 269.81%. As a group, “Pharmaceutical preparations” companies have a potential upside of 2,430.48%. Given CervoMed’s peers higher possible upside, analysts plainly believe CervoMed has less favorable growth aspects than its peers.

Profitability

This table compares CervoMed and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CervoMed	-118.68%	-44.11%	-39.81%
CervoMed Competitors	-3,399.87%	-235.11%	-32.77%

Insider and Institutional Ownership

25.1% of CervoMed shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 13.5% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CervoMed peers beat CervoMed on 7 of the 13 factors compared.

About CervoMed

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.